Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the Irish Longitudinal Study on Ageing.

Slides:



Advertisements
Similar presentations
NCEP ATP III Cholesterol Guidelines and Updates
Advertisements

©PPRNet 2014 Impact of Patient Engagement on Treatment Decisions and Patient-Centered Outcomes in the Implementation of New Guidelines for the Treatment.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
CVD Prevention in Primary Care CVD Guidelines Symposium Wednesday 3 rd Novemeber 2010 Dr John Cox FRCPI FRCGP.
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Developing Cardiac Rehabilitation in Vietnam Dr Juliette Hussey School of Medicine Trinity College Dublin Ireland.
TILDA and the HRB Professor Rose Anne Kenny Trinity College Mercers Institute St James Hospital.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
Modelling the development of, and treatments for, heart disease and stroke. Tushar Chatterjee, Angus Macdonald & Howard Waters Heriot-Watt University,
Cardiovascular Disease Healthy Kansans 2010 Steering Committee Meeting April 22, 2005.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.
Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.
The Management of People at High Risk of CVD Dr Richard Healicon Mel Varvel NHS Improvement.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.
Simplifying Cardiovascular Risk Assessment Mixed Methods Audit of MSF’s NCD Mission in Irbid, Jordan – Interim Results Prepared by Dylan Collins 17 June.
GORING AND WOODCOTE MEDICAL PRACTICE PATIENT PARTICIPATION GROUP (PPG) Cardiovascular Disease 10 September 2016 Slide 1 Open Meeting.
UK Hospitalizations due to Stroke in Prostate Cancer Patients
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Background/Objective
Healthy Eating Similarities and Differences
Journal of the American College of Cardiology
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Hypertension November 2016
Leah Li MRC Centre of Epidemiology for Child Health
John Weeks1, MD Candidate 2017, Justin Hickman1, MD Candidate 2017
Silvio Lopes Alabarse, Japy A
Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,
Safi U. Khan MD; John Pamula MD
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
Cholesterol practice questions
ELIGIBILITY: MRC/BHF Heart Protection Study
39 DEVELOPED HCC by EASL criteria
Prevalence and control of cardiovascular risk factors using a German sample – Findings from the STAAB Cohort Study Theresa Tiffe1,3, Götz Gelbrich1,2,
Cardiovascular risk factors: are they useful screening tests?
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Neil J. Stone et al. JACC 2014;63:
Systolic Blood Pressure Intervention Trial (SPRINT)
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Baseline characteristics of HPS participants by prior diabetes
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
European Heart Association Journal 2007 April
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study by James P Sheppard, Kate Fletcher, Richard J McManus,
by Peter Ueda, Thomas Wai-Chun Lung, Philip Clarke, and Goodarz Danaei
O.L.Reuchlin gebruik van CT binnen de cardiogie
Contemporary Evidence-Based Guidelines
The Cardiovascular Health Study:
Volume 375, Issue 9725, Pages (May 2010)
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Hypertension November 2016
Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.
Goals & Guidelines A summary of international guidelines for CHD
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
2017/18 National Diabetes Audit Cambridgeshire and Peterborough CCG local summary Public Health Intelligence, Cambridgeshire and Peterborough : April 2019.
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.
Presentation transcript:

Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the Irish Longitudinal Study on Ageing (TILDA) C. Murphy 1, K. Bennett 1, E. Shelley 2, I. Graham 3, T. Fahey 2, RA Kenny1 1. Trinity College Dublin 2. Royal College of Surgeons in Ireland 3. Department of Cardiology, St. James Hospital, Dublin. Introduction The role of statins in the secondary prevention of cardiovascular disease (CVD) is well established. Statin therapy is also recommended as part of the management strategy for diabetics. In asymptomatic individuals, statins are recommended if the Systematic COronary Risk Estimation (SCORE) of 10 year CVD mortality is high (≥5% and <10%) or very high (≥10%) and Low- Density Lipoprotein (LDL-C) levels are above defined intervention thresholds. Aim and Objectives To examine the extent to which statins are used by adults at high risk of CVD compared to European clinical guidelines. The high risk groups examined are those with Known CVD Known diabetes High or very high SCORE risk Results The response rate to the TILDA survey as a whole was 62%. In those aged 50-64 years the mean age was 56.7 years, 45% were male (Table 1). Almost 5% (n=166) were known to have CVD and 4.2% (n=141) were known to have diabetes (Figure 1). SCORE risk was estimated in those without CVD or diabetes (n=3065), 40.9% were at low risk, 54.4% at moderate risk, 4.0% at high risk and 0.6% at very high risk of 10 year CVD mortality. In total 4.6% (n=142) were classified at high or very high risk for CVD mortality; this was higher in males compared to females (Figure 2). In those with CVD, 68.6% (95% CI 61.5% to 75.9%) were taking statins (Figure 3). In diabetics, 57.4% (95% CI 49.1%-65.7%) were on statins and in those whose SCORE risk was ≥5% only 19.7% (95% CI 13.0% to 26.3%) were found to be taking statins. Over a third (38.5%) of those with known CVD, 46.8% of those with known diabetes and 85.2% of those with a SCORE risk ≥5% were at or above the low-density lipoprotein cholesterol (LDL-C) target of 2.5 mmol/L specified in the 2007 European guidelines (Table 2). Higher proportions in each high risk group were at or above the total cholesterol guideline target of 4.5 mmol/L (Table 3). In 2012 the target LDL-C for those with CVD was reduced to <1.8mmol/L in the European guidelines. Just over a quarter of the CVD group (27.7%) were at or below the recommended LDL-C target for secondary prevention using the updated guidelines which were published within a year of data collection completion. Based on the 2012 guidelines we estimate that approximately 52,000 individuals aged 50-64 yrs were on suboptimal statin treatment compared to the clinical guideline recommendations. Full paper can be accessed at: BMJ Open 2015;5:e008017 doi:10.1136/bmjopen- 2015-008017 Table 1: Characteristics of the sample (50-64 years) Table 2: Percentage of individuals with LDL-C above and below cut-offs defined in European guidelines 2007 Table 3: Percentage of individuals with serum total cholesterol above and below cut-offs defined in European guidelines 2007 Method Cross-sectional study TILDA baseline wave (2009-2011) Representative sample of community living older adults in Ireland aged 50 years and older Home based interview Health centre or home based health assessment Analysis limited to those aged 50-64 years Self-report of CVD (angina, myocardial infarction, bypass surgery, angioplasty or stent, stroke or transient ischaemic attack) and diabetes based on ever having a doctor’s diagnosis CVD risk in those without CVD or diabetes was calculated using the SCORE ‘low’ risk country equations Conclusion Despite strong evidence and clinical guidelines supporting the use of statins for secondary prevention of CVD, this study reveals a gap between guidelines and clinical practice in this cohort. An immediate policy response is required to strengthen secondary prevention for those with existing CVD. For the remainder of the population without evidence of CVD, population strategies for primary prevention are required as well as opportunistic risk assessment to identify those at high risk of future CVD in order to establish best practice in primary prevention Figure 2: SCORE 10 year risk of CVD mortality by sex in those without CVD or diabetes Contact Catriona Murphy, TILDA, Lincoln Gate, Trinity College, Dublin 2 catriona.murphy@tcd.ie Phone: 01 896 4342 Figure 1: Flow chart of the number of participants included in the analysis Figure 3: Statin utilisation in groups at high risk of CVD TILDA is supported by the Department of Health, Irish Life and the Atlantic Philanthropies. This work was funded by the Health Research Board in Ireland under Grant No: ICE/2012/7. We acknowledge Dr. Marie Therese Cooney for providing STATA code for SCORE.